hERG1 behaves as biomarker of progression to adenocarcinoma in Barrett's esophagus and can be exploited for a novel endoscopic surveillance

Barrett's esophagus (BE) is the only well-known precursor lesion of esophageal adenocarcinoma (EA). The exact estimates of the annual progression rate from BE to EA vary from 0.07% to 3.6%. The identification of BE patients at higher risk to progress to EA is hence mandatory, although difficult...

Descripción completa

Detalles Bibliográficos
Autores principales: Lastraioli, Elena, Lottini, Tiziano, Iorio, Jessica, Freschi, Giancarlo, Fazi, Marilena, Duranti, Claudia, Carraresi, Laura, Messerini, Luca, Taddei, Antonio, Ringressi, Maria Novella, Salemme, Marianna, Villanacci, Vincenzo, Vindigni, Carla, Tomezzoli, Anna, Mendola, Roberta La, Bencivenga, Maria, Compagnoni, Bruno, Chiudinelli, Mariella, Saragoni, Luca, Manzi, Ilaria, Manzoni, Giovanni De, Bechi, Paolo, Boni, Luca, Arcangeli, Annarosa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312329/
https://www.ncbi.nlm.nih.gov/pubmed/27517748
http://dx.doi.org/10.18632/oncotarget.11149

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5312329/
https://www.ncbi.nlm.nih.gov/pubmed/27517748
http://dx.doi.org/10.18632/oncotarget.11149

Ejemplares similares